Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NVNO

NVNO - enVVeno Medical Corporation Stock Price, Fair Value and News

$10.81+0.57 (+5.57%)
Market Closed

14/100

NVNO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

NVNO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$9.35

Target 3M

$10.52

Target 6M

$9.94

NVNO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVNO Price Action

Last 7 days

-1.0%

Last 30 days

-6.7%

Last 90 days

-55.7%

Trailing 12 Months

-90.3%

NVNO RSI Chart

NVNO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVNO Valuation

Market Cap

218.5M

Price/Earnings (Trailing)

-9.95

Price/Sales (Trailing)

406.96

Price/Free Cashflow

-13.69

NVNO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$9.35

Target 3M

$10.52

Target 6M

$9.94

NVNO Fundamentals

NVNO Revenue

Revenue (TTM)

537.0K

Rev. Growth (Yr)

86.17%

Rev. Growth (Qtr)

-10.26%

NVNO Earnings

Earnings (TTM)

-22.0M

Earnings Growth (Yr)

19.55%

Earnings Growth (Qtr)

32.19%

NVNO Profitability

Return on Equity

-74.59%

Return on Assets

-67.89%

Free Cashflow Yield

-7.31%

NVNO Investor Care

Shares Dilution (1Y)

15.28%

Diluted EPS (TTM)

-1.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250421.0K537.0K0
2024194.0K228.0K278.0K0
2023201.0K203.0K172.0K180.0K
202220.0K54.0K122.0K161.0K
20213.0K10.0K15.0K0
2019186.7K103.4K61.7K31.2K
2018363.2K304.3K245.4K186.6K
2017000422.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About enVVeno Medical Corporation

NVNO
enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
 CEO
 WEBSITEenvveno.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES30

enVVeno Medical Corporation Frequently Asked Questions

NVNO is the stock ticker symbol of enVVeno Medical Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of enVVeno Medical Corporation is 218.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NVNO's fair value in chart for subscribers.

The fair value guage provides a quick view whether NVNO is over valued or under valued. Whether enVVeno Medical Corporation is cheap or expensive depends on the assumptions which impact enVVeno Medical Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVNO.

As of Wed Jan 28 2026, NVNO's PE ratio (Price to Earnings) is -9.95 and Price to Sales (PS) ratio is 406.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVNO PE ratio will change depending on the future growth rate expectations of investors.